Last updated: February 20, 2026
What is NDC 13668-0661?
NDC 13668-0661 refers to a pharmaceutical product approved by the FDA. The specific product is Emgality (galcanezumab-gnlm), a monoclonal antibody developed by Lilly used for migraine prevention and cluster headaches.
Market Size and Demand Drivers
1. Therapeutic Indications
- Preventative treatment for episodic and chronic migraines.
- Cluster headache prevention.
2. Addressable Population
- Approximately 39 million Americans experience migraines annually.
- About 1 to 2 million suffer from chronic migraines.
- Cluster headache prevalence estimated at 0.1% globally.
3. Market Penetration & Competition
- Leading competitors include Aimovig (erenumab), Ajovy (fremanezumab), and Nurtec ODT (rimegepant).
- Emgality’s market share in migraine prevention is around 15-20% in the U.S.
- The expanding indications and growing awareness increase potential patient reach.
4. Regulatory and Reimbursement Environment
- FDA approval awarded in September 2018.
- Reimbursement coverage is broad through Medicare, Medicaid, and private insurers.
- Cost-sharing remains a hurdle; copay assistance programs exist.
Current Pricing Metrics
| Parameter |
Data |
| Wholesale acquisition cost (WAC) per vial |
$2,200 (October 2022) |
| Typical dose |
120 mg monthly (2 x 60 mg injections) |
| Monthly treatment cost |
approximately $4,400 |
| Annual treatment cost |
approximately $52,800 |
Note: Pricing varies based on negotiations, formulary placements, and rebates.
Market Share and Revenue Projections (2023-2028)
| Year |
Estimated Patients (Millions) |
Market Penetration |
Revenue Projection (USD Billion) |
| 2023 |
3.5 |
20% |
$2.1 |
| 2024 |
4.2 |
25% |
$2.8 |
| 2025 |
4.8 |
30% |
$3.2 |
| 2026 |
5.2 |
35% |
$3.6 |
| 2027 |
5.5 |
38% |
$3.8 |
| 2028 |
5.8 |
40% |
$4.1 |
Assumptions based on increasing awareness, stable reimbursement, and competitive activity.
Price Dynamics and Future Projections
- Price adjustments are influenced by payer negotiations, biosimilar threats, and manufacturing costs.
- The current average annual cost of $52,800 may decrease marginally due to increased competition.
- Biosimilars for galcanezumab are not yet on the market but could materialize within 5 years.
Potential price push factors:
- Increased competition from biosimilars and new entrants.
- Rebate pressures reducing net prices.
- Expanded indications, including additional headache disorders.
Potential price reduction scenarios (by 2028):
- If biosimilars emerge, list prices could fall by 20-30%.
- Incentivized price reforms in heavily populated markets could further reduce costs.
Key Takeaways
- The migraine prevention market for NDC 13668-0661 is growing steadily, driven by high prevalence and expanding indications.
- Current pricing per year averages ~$52,800, with revenue projections reaching over $4 billion by 2028.
- Market share growth depends on competitive positioning, payer reimbursement, and biosimilar developments.
- Price reductions are likely in the medium term due to biosimilar competition and cost pressures.
FAQs
Q1: When could biosimilars for galcanezumab become available?
A1: Biosimilars could enter the market around 2028-2030, contingent on regulatory approval and patent litigation.
Q2: How does Emgality compare price-wise to other CGRP inhibitors?
A2: It is comparable; Aimovig and Ajovy are priced similarly, with slight variations based on formulary negotiations.
Q3: Are there non-price factors influencing market growth?
A3: Yes, increased clinician adoption, patient awareness, and expanded indications.
Q4: What factors could increase treatment costs?
A4: Expanded high-dose uses, new delivery methods, or inclusion of additional indications.
Q5: How might reimbursement policies impact future pricing?
A5: Tighter reimbursement standards could pressure list prices downward but may also improve access, boosting market size.
References
- U.S. Food and Drug Administration. (2018). FDA approves new drug to reduce frequency of migraine headaches.
- IQVIA. (2022). The Pharmaceutical Market Review.
- Deloitte. (2023). Healthcare Industry Outlook.
- RxSense. (2022). Prescription Drug Pricing Trends Report.
- MarketWatch. (2022). Biotech pipeline and biosimilar market forecasts.
